ArticleMedicine2017

Intermediate-stage hepatocellular carcinoma patients with a high HBV-DNA load may benefit from postoperative anti-hepatitis B virus therapy.

Shaozhen Rui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.